Vyne Therapeutics

Yahoo Finance • 5 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Agape ATP Corporation 231,897,993 0.154 0.1273 0.1347 +0.0447 VYNE Thera... Full story

Yahoo Finance • 7 months ago

VYNE Therapeutics GAAP EPS of -$0.17 misses by $0.04, revenue of $0.2M beats by $0.1M

* VYNE Therapeutics press release [https://seekingalpha.com/pr/20296695-vyne-therapeutics-reports-2025-third-quarter-financial-results-and-provides-business-update] (VYNE [https://seekingalpha.com/symbol/VYNE]): Q3 GAAP EPS of -$0.17 mis... Full story

Yahoo Finance • 10 months ago

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment landscape is evolving with a shift tow... Full story

Yahoo Finance • 10 months ago

The trading volume of these stocks is deviating from the norm in today's session.

Which stocks have an unusual volume on Tuesday? [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SVIIR [https://www.chartmill.com/stock/quote/SVIIR/profile] 1.82% 295.38K shares of SPRING VALLEY ACQUISI... Full story

Yahoo Finance • 10 months ago

Sector Update: Health Care Stocks Decline in Late Afternoon Trading

Health care stocks decreased late Wednesday afternoon with the NYSE Health Care Index dropping 0.7% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 10 months ago

VYNE's vitiligo treatment fails primary endpoint in phase 2b trial

BRIDGEWATER, N.J. - VYNE Therapeutics Inc. (NASDAQ:VYNE), a clinical-stage biotech company with a market capitalization of $6.45 million, announced Wednesday that its Phase 2b trial evaluating Repibresib gel for nonsegmental vitiligo faile... Full story

Yahoo Finance • 11 months ago

BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data

Investing.com - BTIG has reiterated its Buy rating and $5.00 price target on VYNE Therapeutics (NASDAQ:VYNE), currently trading at $1.51 with a market cap of $25.2 million. InvestingPro data shows analysts maintain a strong buy consensus w... Full story

Yahoo Finance • 11 months ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory... Full story

Yahoo Finance • last year

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammator... Full story

Yahoo Finance • last year

VYNE Therapeutics to Participate in March Investor Conferences

BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory... Full story

Yahoo Finance • last year

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed to provide key insights into VYN202... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov.... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the trea... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing, VYNE expects to ini... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the trea... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinicall... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inh... Full story

Yahoo Finance • 3 years ago

VYNE Therapeutics to Attend BIO International Convention

BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies fo... Full story